Farthing Michael J G
St George's, University of London, London, SW17 0RE, United Kingdom.
Sci Eng Ethics. 2006 Jan;12(1):41-52. doi: 10.1007/pl00022267.
Although authors are usually considered to be the main perpetrators of research and publication misconduct, any person involved in the process has the potential to offend. Editors may breach ethical standards particularly with respect to conflicts of interest. In the same way that authors are now required to declare competing interests, notably commercial affiliations, financial interests and personal connections, so must editors. Editors can influence the chances of acceptance or rejection of a paper by reviewer selection. Reviewers should also be ready to disclose conflicts of interest. They must ensure that their reviews are evidence based and free from destructive criticism driven by self interest. It seems likely that ultimately we will progressively move towards 'open' peer review in which both the authors and the reviewers are known to each other. There is an urgent need for increased transparency of the relationship between editors and owners. The events of the last few years indicate that unless this interface is fully understood by all parties, conflicts may arise. There is also a need for a radical overhaul in the relationship between journals, journal editors and the biomedical industry. It is now increasingly accepted that all clinical trials should be registered in a centrally held database and that protocols should include the primary and secondary outcome measures and the intended approach to data analysis thereby avoiding opportunistic post hoc analyses. However, the even more radical proposal that journals should cease to publish clinical trials sponsored by industry deserves wider debate.
尽管作者通常被视为研究和出版不当行为的主要肇事者,但参与该过程的任何人都有可能违规。编辑可能会违反道德标准,尤其是在利益冲突方面。与现在要求作者声明竞争利益(特别是商业附属关系、经济利益和个人关系)一样,编辑也必须这样做。编辑可以通过选择审稿人来影响论文被接受或拒绝的机会。审稿人也应该准备好披露利益冲突。他们必须确保自己的评审基于证据,且不受私利驱动的破坏性批评的影响。最终,我们似乎将逐步走向“开放”同行评审,即作者和审稿人相互知晓。迫切需要提高编辑与期刊所有者之间关系的透明度。过去几年的事件表明,除非各方都充分理解这种关系,否则可能会产生冲突。期刊、期刊编辑与生物医学行业之间的关系也需要彻底改革。现在越来越多人接受所有临床试验都应在一个集中的数据库中注册,并且方案应包括主要和次要结局指标以及数据分析的预期方法,从而避免机会主义的事后分析。然而,关于期刊应停止发表由行业赞助的临床试验这一更为激进的提议,值得进行更广泛的辩论。